| INTRODUC TI ON
In the battle against cancer, immunotherapeutic approaches gain continuously increasing importance. A prominent representative is chimeric antigen receptor (CAR-) T cell therapy that has already revealed impressive results in haematological malignancies [1] [2] [3] , highlighting its strong potential. This has led to the recent approval of two CD19 CAR-T cell constructs, tisagenlecleucel (Kymriah, Novartis, Basel, Switzerland) and axicabtagene ciloleucel (Yescarta, Kite Foster City, CA, USA) in the United States and the European Union. [1, 2] The structural design of a CAR comprises a single-chain variable fragment (scFv) derived from a monoclonal antibody targeting a cancer-specific antigen. [4, 5] Intracellular components are a signalling domain derived from the T-cell receptor (TCR), typically the zeta subunit of the CD3 complex, and one or more co-stimulatory motifs, for example, CD28, 4-1BB or OX40. [4, 5] CAR constructs are then able to recognize whole surface proteins on cancer cells independent of antigen processing and MHC presentation. [6] When clinically used, the initial action of CAR-T cell therapy is the extraction of T cells from a patient's apheresis product. [7] After that, T cells are ex vivo genetically transduced with a CAR construct and are subsequently stimulated and expanded to obtain a high number of engineered cells before being reinfused into the patient (Figure 1 ). [7] Prior to CAR-T cell administration, conditioning chemotherapy regimen is given in order to increase therapeutic power by depletion of autologous lymphocytes and immunosuppressive cells. [7, 8] After the huge success of CAR-T cells in haematological malignancies, its efficacy is currently evaluated in different solid tumors. [9] [10] [11] Especially in the context of immunotherapy, a commonly examined tumor model in a preclinical as well as clinical setting is melanoma (Table 1) , since it is known for its immunogenic features. [12, 13] However, first results were not as compelling as for haematological malignancies [9] [10] [11] , due to the fact that CAR-T cells need to cope with several challenges when used in solid tumors ( Figure 2 ). One obstacle is defined by the insufficient migration of CAR-T cells from the blood vessels to the tumor site, which is necessary for effective tumor eradication. [14] [15] [16] Once entered, CAR-T cells need to struggle through the unfavourable tumor microenvironment (TME) in order to induce a potent anti-tumor immune response. [17] [18] [19] Finally, the selection of the optimal target antigen is an important step, as T cells should be equipped with a CAR recognizing an antigen that is exclusively expressed on cancer cells rather than on healthy tissue to prevent on-target/ off-tumor toxicities. [20, 21] Concerning tumor antigens, the occurrence of immune escape mechanisms developed by tumor cells to bypass immune recognition, for example, downregulation or loss of the target antigen, represents further barriers that need to be addressed. [22, 23] In order to improve CAR-T cell therapy for the use in solid tumors, different groups are currently working on novel approaches. In this viewpoint article, we give an overview of the above-mentioned challenges faced by CAR-T cells in solid tumors and discuss potential strategies and approaches to improve the therapy, particularly in melanoma. In this context, we will also discuss the role of a possible combined therapy with other immunotherapeutic agents to alter the TME and thus to boost CAR-T cell efficacy as a potential treatment strategy.
| ENHAN CINGT-CELLMI G R ATI ON
During cancer development and progression, TME and surrounding stromal tissue pass through dynamic changes. [24] These alterations are mediated through increased extracellular matrix (ECM) and growth factor production and secretion resulting in continuous growth of fibrous and connective tissue around the tumor. [25] This process is known as desmoplasia and interferes with the ability of T cells to migrate, as observed in pancreatic cancer, melanoma and other solid tumors. [26] [27] [28] Initial case series and studies showed that the desmoplastic type of melanoma displays a high tendency for local recurrences, based on its apparently aggressive clinical behaviour. [29, 30] Especially for CAR-T cell therapy, new strategies are required to circumvent these hurdles. Current approaches to achieve this goal include the generation of optimized CAR-T cells with the additional ability (a) to easily overcome physical barriers, such as endothelial cells [31, 32] and the ECM of stromal cells [33, 34] and (b) to intensify extravasation into the tumor tissue through defined chemokine-chemokine receptor interactions. [35, 36] The subendothelial basement membrane and the ECM as an integral component of the stroma need to be actively degraded by CAR-T cells during the extravasation process into the tumor
Blood is taken from the patient via apheresis for T-cell enrichment. Next, T cells are genetically transduced with a tumor antigen-specific CAR and are subsequently activated to boost the expansion of cells. In the last step, CAR-T cells are reinfused into the patient, usually after receiving conditioning chemotherapy to deplete autologous lymphocytes and immunosuppressive cells. tissue. Heparan sulphate proteoglycans (HSPGs) represent one of the main components of the ECM [37, 38] , and thus, T cells attacking stroma-enriched solid tumors should be able to degrade HSPGs in order to access tumor cells and exert anti-tumor effects. In this context, Caruana et al. observed that after engineering CAR-T cells to express heparanase, an enzyme which degrades HSPGs, indeed enhanced tumor T-cell infiltration and anti-tumor activity in vitro and in vivo mouse models were detected. [37] Clinical data have not been reported to date, suggesting that further preclinical analysis will be performed.
Additionally, the expression of specific chemokine receptors on effector cells matching the chemokines produced by either the tumor or tumor-associated cells displays a novel strategy. [39, 40] Kershaw and colleagues revealed that deficiencies in T-cell chemotaxis towards tumor cells were overcome by transgenic expression of the C-X-C motif chemokine receptor 2 (CXCR2), which recognized a specific tumor-produced chemokine. [41] Similarly, Di
Stasi et al. demonstrated that overexpression of the C-C chemokine receptor type 4 (CCR4) by CD30-CAR expressing T cells enhanced migration in response to Hodgkin's lymphoma through secreting its ligand CCL17 in murine xenograft experiments. [42] In a study performed by Craddock and colleagues, enhanced tumor migration of GD2-specific CAR-T cells was detected by expression of the C-C chemokine receptor type 2 (CCR2b). [43] Comparable results were further observed in another study, where expression of a functional CCR2 cytokine receptor enhanced tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific CAR. [44] There are various numbers of chemokines expressed by primary melanoma cells as well as by melanoma metastases. [45] However, studies on T cells additionally expressing a melanoma antigen-specific CAR and a melanomaspecific chemokine receptor have not been reported in the literature to date.
By using intralesional rather than intravenous CAR-T cell injections, both, physical obstacles and extravasation into tumor tissue, could be circumvented. A previous clinical study evaluating intracranial administration of T cells expressing a first-generation IL13Rα2-targeted CAR in patients with glioblastoma revealed transient antiglioma responses with no high-grade therapy-related side effects. [46, 47] Based on these initial results, the authors modified the CAR-T cells to improve anti-tumor potency and T-cell persistence by incorporating a 4-1BB co-stimulatory domain to a mutated IgG4-Fc linker. [48] [49] [50] One patient receiving intracranial infusions of these optimized second-generation IL13Rα2-targeted CAR-T cells showed regression of all intracranial and spinal tumors, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. [48] In contrast to glioblastoma, melanoma patients can develop multiple metastases in different organ systems, complicating a direct application of CAR-T cells. However, this approach could be effective and reasonable in patients with defined and limited metastasis. Clinical data have not been reported to date on melanoma patients receiving intralesional CAR-T cell injections.
| COPINGWITHTHE IMMUNOSUPPRE SS IVETUMOR MICROENVIRONMENT
After extravasation, CAR-T cells need to struggle through the unfavourable TME in order to induce a potent anti-tumor immune response for tumor cell eradication. [18] Factors influencing T-cell function within the TME include (a) activation of inhibitory immune checkpoint receptors on T cells, for example, programmed cell death protein 1 (PD-1) through ligation to tumor and stromal cells [51] [52] [53] and (b) the predominantly anti-inflammatory cytokine milieu with
CAR-T cells have to encounter several problems that directly interfere with the outcome of the treatment in patients with solid tumors. First, CAR-T cells need to migrate towards the tumor site. This outlines a physical barrier as engineered T cells have to leave blood vessels and follow chemokine gradients to reach the cancer. After extravasation, CAR-T cells need to struggle through the unfavourable tumor microenvironment (TME). Anti-inflammatory cytokines secreted by, for example, regulatory T cells (T regs ), as well as inhibitory receptors, which are upregulated on engineered T cells in the TME, prevent CAR-T cells to efficiently eliminate cancer cells. Moreover, a general hurdle of CAR-T cell therapy is the identification of an ideal target antigen. In order to avoid recognition of healthy tissue, an antigen has to be selected that is exclusively expressed on tumor cells. When an ideal tumorassociated antigen is determined, the occurrence of antigen loss in the context of immune escape mechanisms defines a further obstacle that needs to be counteracted. interleukin-10 (IL-10), transforming growth factor (TGF)-beta and other cytokines [54, 55] produced by immunosuppressive cells, for example, regulatory T cells (T regs ). [56] [57] [58] PD-1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) represent the two major and highly investigated immune checkpoint molecules. [51] [52] [53] Both affect T lymphocytes at different stages of differentiation and at different anatomical locations within the human body. [59] After antigen-specific stimulation, CTLA-4 upregulation is mainly induced on lymphoid tissues and naïve T cells. [60] CTLA-4-blocking therapies suppress negative signals delivered by CTLA-4, permitting sustained T-cell activation and proliferation in the lymphoid tissue. [59, 60] The major role of the PD-1/PD-L1 axis is present at a later stage of T-cell activation. [59, 61] In peripheral tissues including tumors, activated T lymphocytes upregulate PD-1 expression. [59, 61] The expression is triggered by inflammatory signals in the tissues, which downregulate the function of T cells through binding to its ligand as a feedback mechanism to limit tissue damage. [59, 61] In this context, T-cell exhaustion defines a state of terminal T-cell differentiation and is induced by prolonged exposure to high levels of antigens. [59, 61] Thus, CTLA-4 is predominantly involved in immuneimmune cell interactions in lymphoid tissue, whereas PD-1 targets the tumor-immune cell interaction on the tumor site.
Antagonistic anti-PD-1 or anti-CTLA-4 antibodies are already standard therapy in, for example, metastatic melanoma patients. [62, 63] The combined use of these two antibodies even further improved the progression-free survival and objective response rate compared to the mono-therapies [64] , highlighting the efficacy of [ 65] A considerable amount of preclinical work was performed by various groups to improve CAR-T cell therapy in solid tumors by simultaneously blocking these inhibitory checkpoint molecules. Methods to achieve this goal included CAR transfection and additional stable knockout of the inhibitory receptors on these CAR-T cells using the CRISPR/Cas9 system [66] [67] [68] , transient downregulation of these receptors using siRNA electroporation [69] or the generation of CAR-T cells secreting immune checkpoint inhibitors upon stimulation with the target antigen. [70, 71] In addition, clinical cases in cancer patients have been recently published describing the infusion of CTLA-4-or PD-1-blocking monoclonal antibodies in combination with adoptive cell transfer revealing promising responses. [72, 73] Thus, the combination of PD-1 or CTLA-4 checkpoint blockade antibodies with CAR-T cell therapy in different tumors is now investigated within clinical trials. [32, 73] Especially in metastatic melanoma, where checkpoint blockade antibodies are already standard therapy, the combined use appears to be a promising strategy in order to improve CAR T-cell efficacy.
Within the TME, cytolytic capacity of CAR-T cells is further hampered by immunosuppressive cytokines, for example, IL-10 and TGF-β. [54, 55] Especially, T regs , representing one of the predominant cell types in the TME, produce a significant level of these inhibitory cytokines. [56] The observation that the activity of anti-CTLA-4 antibody leads to selective Fc-γR-mediated depletion of T regs within tumor lesions in mice [74] indicates another reason for its combined use together with CAR-T cell infusion to enhance engineered T-cell treatment. Another novel strategy to circumvent the negative effect by immunosuppressive cytokines was reported by a research group from the University of Pennsylvania. They generated CAR-T cells recognizing prostatespecific membrane antigen (PSMA) and additionally engineered them to co-express a dominant-negative TGF-β receptor (dnTGF-βRII). Upon expression of the dominant-negative TGF-β receptor in CAR-T cells, an increased proliferation of these engineered lymphocytes, enhanced cytokine secretion, resistance to exhaustion, long-term in vivo persistence and the induction of tumor eradication in aggressive human prostate cancer mouse models was observed. [75] Based on these promising results, a phase I clinical trial to assess these CAR-T cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer was initiated and is currently running.
[75]
| EFFEC TIVEANTI G ENTARG E TING
Finally, the selection of the optimal target antigen is another important step (a) to induce potent anti-tumor immune responses for tumor cell eradication and (b) to avoid major side effects, as the target antigen should ideally not be expressed in non-malignant cells. [18, 20] Thus, to bring CAR-T cell therapy for metastatic melanoma from bench to bedside, an optimal target antigen needs to be accurately investigated in a preclinical setting.
Chondroitin sulphate proteoglycan 4 (CSPG4; also called melanoma-associated chondroitin sulphate proteoglycan, MCSP or high molecular weight melanoma-associated antigen, HMW-MAA)
is expressed in about 90% of melanomas [76] and other malignancies, for example, sarcomas and gliomas. [77, 78] It plays a significant role in melanoma progression by influencing adhesion/spreading, migration, invasion and metastasis. [76] As it is not commonly expressed in healthy tissue, CSPG4 may represent an effective target for the use in CAR-T cell therapy of melanoma. However, previous studies have demonstrated that patients undergoing CAR-T cell therapy can show disease progression after an initial efficient therapeutic response, most likely due to so-called "immune escape mechanisms"
developed by tumor cells to bypass immune recognition. These mechanisms include the downregulation or loss of the target antigen. [22, 23] Thus, different groups have worked on new strategies to counteract these mechanisms, with the use of T cells expressing not only one but two introduced tumor-specific receptors being one approach. [79, 80] This could reduce the risk of immune escape, as it is less likely that both tumor antigens recognized by the same T cell will be simultaneously lost or downregulated on the same tumor cell. Our group, for instance, introduced a T-cell receptor and a CAR, both specific for different common melanoma antigens, glycoprotein 100 (gp100) and CSPG4, to generate functional engineered T cells expressing two additional receptors (TETARs). [79] These cells produced cytokines and displayed lytic activity upon recognition of each of their cognate antigens, while no reciprocal inhibition of the receptors occurred. [79] After stimulation with target cells expressing both target antigens, an even enhanced effect was observed. [79] Ruella et al.
also introduced two receptors, a CD19-specific CAR and additionally a CD123-specific CAR, into the same T cell. [80] They observed similar promising results regarding T-cell activation and anti-tumor efficiency in vitro and in a mouse model against B-cell acute lymphoblastic leukaemia (B-ALL) compared to single-expressing CAR-T cells or a pooled combination of both CAR-T cell populations. [80] However, by using two different target antigens, the rate of potential side effects of CAR-T cell therapy, including cytokine release syndrome (CRS), severe neurotoxicity and on-target/offtumor toxicities, may be enhanced as well. [81, 82] As the key cytokine in CRS is interleukin (IL)-6, blocking of the IL-6 receptor with the monoclonal antibody tocilizumab is the appropriate regimen to treat CRS. [83] In CD19-CAR-T cell therapy, which is now an approved standard therapy for therapy-refractory B-ALL, the loss of healthy CD19 + cells can be compensated by supplementing i.v. immunoglobulins. Regarding other antigens, this could be more difficult and dangerous, as shown in a clinical trial with a CAR specific for carbonic anhydrase IX, where severe antigen-specific liver toxicity was seen. [84] In order to counteract potential immune escape mechanisms of tumor cells, as well as to deal with potential fatal side effects, the adoptive transfer of alternative cell populations moves into focus. [85, 86] Natural killer T (NKT) cells, which share characteristics of natural killer (NK) cells and T cells, represent an effective cell subpopulation in pathogen and tumor cell defense. [87, 88] The high number and functionality of NKT cells in blood or tumor was demonstrated to directly correlate with better survival in different human cancers. [88] The advantage of NKT cells over conventional T cells may be their pronounced intrinsic anti-tumor activity through their endogenous TCR [88, 89] and is triggered by glycolipids presented via CD1d on antigen-presenting cells. [88, 89] In a phase 1 trial with melanoma patients, the use of NKT cells was shown to be feasible. [90] However, this trial revealed that this treatment regimen requires further improvement to yield clinical efficacy. [90] Methods to improve the tumor-specific activation of these cells were developed, and the combination of this cell population's intrinsic anti-tumor activity with a CAR-mediated specificity defined a new approach. [91, 92] In preclinical experiments, NKT cells retrovirally transduced with
CARs against GD2 and CD19 already proved their effectiveness. [91, 92] In one of our studies, NKT cells were transiently equipped with a CAR specific for the melanoma antigen CSPG4 using mRNAelectroporation and in vitro functionality after co-incubation with melanoma cells was analyzed. [93] The CAR-transfected NKT cells produced lower quantities of cytokines, for example, TNF and IFNγ, compared to CD8 + CAR-T cells. [93] The most important function in cancer therapy, however, is the specific lytic activity of transfected cells against tumor cells, which was similar for CAR-NKT cells and CAR-transfected CD8 + T cells in our in vitro study. [93] Further preclinical analysis is required for a potential use in a clinical setting.
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